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Abstract
Genetic variation in innate immune response genes contributes to inter-individual differences in disease manifestation and
degree of complications upon infection. We recently described an association of single nucleotide polymorphisms (SNPs) in
TLR9 with susceptibility to meningococcal meningitis (MM). In this study, we investigate the association of SNPs in multiple
pathogen recognition and immune response genes with clinical features that determine severity and outcome (especially
hearing loss) of childhood MM and pneumococcal meningitis (PM). Eleven SNPs in seven genes (TLR2, TLR4, TLR9, NOD1,
NOD2, CASP1, and TRAIL) were genotyped in 393 survivors of childhood bacterial meningitis (BM) (327 MM patients and
66 PM patients). Genotype distributions of single SNPs and combination of SNPs were compared between thirteen clinical
characteristics associated with severity of BM. After correction for multiple testing, TLR4+896 mutant alleles were highly
associated with post-meningitis hearing loss, especially MM (p = 0.001, OR 4.0 for BM, p = 0.0004, OR 6.2 for MM). In
a multigene analysis, combined carriership of the TLR2+2477 wild type (WT) with TLR4+896 mutant alleles increases the risk
of hearing loss (p,0.0001, OR 5.7 in BM and p = 0.0001, OR 7.6 in MM). Carriage of one or both mutant alleles in TLR4+896
and TLR9 -1237 increases the risk for hearing loss (p = 0.0006, OR 4.1 in BM). SNPs in immune response genes contribute to
differences in clinical severity and outcome of BM. The TLR system seems to play an important role in the immune response
to BM and subsequent neuronal damage as well as in cochlear inflammation. Genetic markers may be used for identification
of high-risk patients by creating prediction rules for post-meningitis hearing loss and other sequelae, and provide more
insight in the complex immune response in the CNS possibly resulting in new therapeutic interventions.
Citation: van Well GTJ, Sanders MS, Ouburg S, van Furth AM, Morre´ SA (2012) Polymorphisms in Toll-Like Receptors 2, 4, and 9 Are Highly Associated with
Hearing Loss in Survivors of Bacterial Meningitis. PLoS ONE 7(5): e35837. doi:10.1371/journal.pone.0035837
Editor: Heiman Frank Louis Wertheim, Oxford University, VietNam
Received September 22, 2011; Accepted March 23, 2012; Published May 25, 2012
Copyright:  2012 van Well et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: samorretravel@yahoo.co.uk
. These authors contributed equally to this work.
Introduction
Bacterial meningitis (BM) is a serious infectious disease of the
central nervous system (CNS). Despite worldwide immunization
programs and improvement of antimicrobial and anti-inflamma-
tory therapy, BM is still responsible for substantial mortality in
both developing and developed countries. The clinical pre-
sentation, severity and outcome of BM are highly diverse.
Mortality is four to ten percent [1] and 20% of survivors develop
neurological sequelae, ranging from learning and behavioral
disorders to deafness, seizures, and motor deficits in 13% of cases
[2]. Considerable evidence implicates that genetic variation in
microbial recognition genes is associated with altered host
responses to infection and the degree of post-infectious complica-
tions [3].
Pathogen recognition receptors (PRRs), present on various cells,
including microglia and astrocytes inside the CNS [4], recognize
pathogen-associated molecular patterns (PAMPs). High affinity
binding activates nuclear factor kappa B (NFkB) and the
subsequent genetic transcription of pro-inflammatory cytokines.
Toll-like receptors (TLRs) and nucleotide-binding oligomerisation
domain-containing proteins (NODs) are two major groups of
PRRs.
We recently reported an association of single nucleotide
polymorphisms (SNPs) in TLR9 with susceptibility to meningo-
coccal meningitis (MM) [5]. Several studies have shown that SNPs
in innate immune response genes affect the clinical course of both
meningococcal and pneumococcal infections [6]. Three papers
focused on genetic variation in innate immune response genes and
BM specifically [5,7,8].
This study aims to assess associations of single SNPs as well as
combinations of SNPs with severity and clinical outcome in post-
meningitis children. The distribution of eleven SNPs in seven
genes involved in pathogen recognition were related to thirteen
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clinical or laboratory variables of BM severity as described in
literature.
We studied TLR2, an extracellular receptor that recognizes
lipoteichoic acid (LTA), present in the cell wall of Streptococcus
pneumoniae [9], and meningococcal porin [10]. TLR2 activation
triggers intracellular signaling via myeloid differentiation protein
88 (MyD88), resulting in pro-inflammatory cytokine production.
TLR22/2 mice, intracerebrally infected with pneumococci,
showed higher mortality, aggravated brain bacterial loads, higher
tumor necrosis factor alpha (TNF-a) concentrations in brain
homogenates, and more damage to the blood-brain barrier (BBB)
[11]. TLR2 -16934 SNPs are associated with higher risk of sepsis
caused by Gram-positive bacteria [12]. TLR2+2477 mutants have
been associated with a reduced responsiveness to Staphylococcus
aureus infections [13].
TLR4 recognizes lipopolysacharide (LPS) in the outer mem-
brane of Neisseria meningitidis. TLR4 triggering activates intracel-
lular signaling via MyD88, resulting in NFkB transcription and
subsequent cytokine production. TLR4+896 mutants cause hypo-
responsiveness to LPS [14] and enhance susceptibility to invasive
meningococcal [15–17] and pneumococcal infections [18].
TLR4+896 mutants are also associated with an increased risk of
developing invasive disease in patients with pneumococcal
infections [18].
TLR9 is an intracellular PRR which recognizes unmethylated
Cytosine-phosphate-Guanine (CpG) motives in bacterial DNA
[19]. Meningococcal [5] and pneumococcal [20] CpG DNA
enters the cell by endocytosis and binds to TLR9. TLR9 activation
triggers the MyD88 dependant pro-inflammatory pathway. We
recently demonstrated that the TLR9+2848 SNP is associated with
decreased susceptibility to MM [5].
NODs are intracellular pattern recognition receptors containing
a Caspase-recruitment domain (CARD). NOD1 and NOD2
recognize degradation products of peptidoglycan (PGN) [21],
a unique and essential component of the cell wall of the vast
majority of bacteria. NOD12/2 mice are more susceptible than
wild type (WT) mice to early sepsis after intranasal administration
of pneumococci [22]. Isolated cultures of murine astrocytes and
microglia constitutively express robust levels of NOD2 after
exposure to both N. meningitidis [23] and S. pneumoniae [24].
NOD1+32556 and NOD2+2209, NOD2+2722, and
NOD2+3020 SNPs are associated with inflammatory bowel disease
[25,26] and share a signaling defect in response to LPS and PGN
[27].
Caspases play an essential role in apoptosis. Activation of
intracellular caspase-1 (CASP1) upon pathogen recognition by
TLRs and NODs defends the host against infection by secretion of
the pro-inflammatory cytokines IL-1b and IL-18 via the IL-1
receptor, and by the induction of apoptosis of infected cells inside
the cell in a molecular structure called the inflammasome [28].
CASP1 levels are up regulated in CSF of patients with BM and
correlate with clinical outcome, assessed by the Glasgow Coma
Scale. CASP12/2 mice intracerebrally infected with S. pneumoniae
show a significantly attenuated increase of IL-1b, lower CSF
leukocytes and an improved clinical status [29]. CASP1 haplotypes
are associated with decreased serum IL-18 levels [30].
TNF-related apoptosis-inducing ligand (TRAIL) is a protein
that induces caspase driven apoptosis upon activation. TRAIL
limits granulocyte driven inflammation in BM. TRAIL levels are
elevated in CSF of patients with BM. TRAIL 2/2 mice show
prolonged inflammation, augmented clinical impairment, and
increased apoptosis in the hippocampus following intrathecal
application of pneumococcal cell wall solution [31]. A highly
polymorphic region in TRAIL, including the TRAIL -692 SNP, has
been identified but not yet linked to human disease [32].
This study aims to describe significant associations of SNPs in
innate immune response genes with severity and outcome in
survivors of childhood BM by comparing genotype distributions
between thirteen clinical severity parameters, including hearing
loss.
Results
Table 1 shows the patient characteristics and the distribution of
the severity variables in our study population. Thirteen clinical
severity variables were studied, including duration of clinical illness
before admission, rectal temperature at admission, and the
laboratory variables CSF leukocyte number, CSF/blood glucose
ratio, CSF protein concentration, blood leukocyte number, C-
reactive protein (CRP) concentrations, blood culture (positive for
meningitis causing organism), convulsions, disturbed consciousness
at admission, ICU-admission, hearing loss, and clinical diagnosis
at discharge (meningitis with or without sepsis). Different numbers
within groups are due to missing or non-determined data in
patient records.
Table 2 shows the genotype distributions of eleven studied SNPs
in our study population, for MM and PM patients. No significant
differences in genotype distributions were observed between MM
and PM patients.
Power Analyses
A priori power analyses show that we have sufficient power at
the 80% threshold in BM patients. However for the rare SNPs we
were not able to reach the 80% threshold in the PM and MM
subgroups. Since BM is relatively rare it is hard to obtain large
numbers of clinically well defined patients.
Genotype and Allele Frequencies
Continuous variables were compared by T-tests or Mann-
Whitney U tests. Duration of clinical illness before admission was
shorter in TLR2 -16934-AA carriers compared to TT and TA
carriers (mean 1.361.4 days in AA carriers versus 1.860.1 days in
TT/TA carriers; p =0.0042). The other continuous variables did
not show differences in genotype distributions (data not shown).
Table 3 shows genotype distributions divided by dichotomous
severity variables with a p-value ,0.05 for MM and PM patients
separately and combined. TLR4+896 AG or GG alleles were
associated with a significantly increased risk of hearing loss
(p =0.001, OR 4.0, 95% CI 1.7–9.4) especially in MM patients (p
=0.0004, OR 6.2 95% CI 2.0–19.5), but was not significant for
PM patients. Carriage of TLR9 -1237 TC or CC mutant alleles
was associated with an increased risk for hearing loss in BM,
especially in PM patients (p =0.023, OR 2,5, 95% CI 1.1-5.4 and
p =0.017, OR 5.0, 95%CI 1.4–17.4, respectively).
CASP1+8404 GG alleles were associated with a decreased in-
cidence of fever in BM and MM patients (p =0.01, OR 0.3, 95%
CI 0.1–0.8 and p =0.018 OR 0.3, 95% CI 0.1 – 0.9). These
associations showed a trend, but appeared not statistically
significant after stringent correction for multiple testing according
to Holm-Bonferroni (p,0.003). No differences in genotype
distributions were observed for other SNPs classified by severity
variables.
Multigene Analysis
Combined carriership of TLR2+2477 GG WT and
TLR4+896 AG mutant alleles significantly increases the risk to
develop hearing loss in BM (p,0.0001, OR 5.7, 95% CI 2.3–14.4,
SNPs Associated with Severity of BM
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in MM patients: p =0.0001, OR 7.6, 95% CI 2.3–24, in PM
patients: p =0.03, OR 13.9, 95% CI 1.3–147). Carriage of one or
more mutant alleles in combined carriership of TLR4+896 and
TLR9 -1237 increases the risk for hearing loss in BM patients (p
=0.0006, OR 4.1, 95% CI 1.8–9.4, in MM patients: p =0.02, OR
4.3 95% CI 1.3–14.2, in PM patients: p =0.003, OR 6.0, 95% CI
1.7–21.3). No significant results were observed for combined
carriership of TLR2 -16934 and TLR2+2477, neither for multiple
SNPs in all three NOD2 SNPs, with regard to the other severity
variables (data not shown).
Multiple Regression Analyses
Backward stepwise logistic regression with hearing loss as
dependent variable resulted in a model containing blood culture,
TLR2, TLR4, TLR9, CASP1, age at diagnosis, rectal temperature,
CSF glucose levels, and gender. All other variables were excluded
from the model during analyses. These variables accurately
(97,8%) predicted BM patients with hearing loss (p = 0.017).
Analyses were repeated for MM and PM patients separately. The
same set of variables predicts hearing loss (98,2%) in PM patients
(p = 0.043), but not in MM patients.
Discussion
In this study we demonstrate for the first time that polymorph-
isms in pathogen recognition receptor genes affect the clinical
course of BM. After correction for multiple testing, we conclude
that duration of clinical illness before admission was shorter in
TLR2- 16934-AA carriers compared to TT or TA carriers.
TLR4+896 mutants are highly associated with post-meningitis
hearing loss and combined carriership of the TLR2+2477 WT
with TLR4+896 mutant alleles as well as the combination of
TLR4+896 mutant alleles with TLR9 -1237 mutant alleles
significantly increases this risk. In multivariable regression analysis,
the same genes are identified to predict hearing loss. In order to
explain these findings, we focus on the pathogenesis of post-
meningitis hearing loss. Since hearing loss occurs in more than
11% of PM survivors and 5% of MM survivors [2] most studies
focus on PM. Bacteria spread from the infected subarachnoid
space to the inner ear through the cochlear aqueduct, along the
eighth cranial nerve or the blood vessels of the blood-labyrinth
barrier [33]. In the peri-lymphatic spaces they induce a suppura-
tive labyrinthitis. As a result, the blood-labyrinth barrier and hair
cells are damaged and neurons in the spiral ganglion show
apoptosis. The inner ear is, similar to the brain, a so-called
immune privileged site: the number of immune competent cells is
small and opsonizing agents are virtually absent under normal
conditions [34]. Once bacteria have reached the inner ear, they
multiply uncontrolled and bacterial autolysis occurs, leading to the
release of bacterial components. The host innate immune response
will be induced by recognition of these components by PRRs and
lead to the transcription of cytokines by resident immunocompe-
tent cells, the local endothelial cells and fibrocytes [34]. There is
increasing evidence for a role of TLRs in mediating cochlear
damage in meningitis [33]. Pneumolysin, recognized by TLR4,
has been identified as a mediator of cochlear damage by its direct
Table 1. Patient characteristics and distribution of 13 clinical severity variables in 393 children with bacterial meningitis.
Continuous variables Median (range) total BM group Median MM Group Median PM group Total BM (MM/PM)
n
Clinical characteristic/Severity variable
Age at admission (years) 2,2 (0–9,5) 2.5 1.0 393 (327/66)
Duration clinical illness before admission
(days)
1,0 (0,5–11,0) 1.0 2.0 387 (321/66)
Rectal temperature (uC) 39,4 (35,0–41,8) 39.2 39.8 362 (299/63)
CSF leukocytes (n/mL) 1013 (0–120810) 1243 600 353 (297/56)
CSF blood/glucose ratio 0,30 (0–1,77) 0.29 0.18 278 (236/42)
CSF protein concentration (g/l) 1,4 (0,01–9,33) 1.7 2.1 324 (58/266)
Blood leukocytes (nx10‘9/l) 16,8 (1,3–93,5) 16.7 20.3 384 (319/65)
CRP concentration (mg/L) 137 (0–768) 135 158 234 (190/44)
Dichotomous variables Total BM Group % MM % PM N % Total determined
n n n n
Clinical characteristic/Severity variable
Male gender 219 56 174 53 45 68 393 (327/66)
Blood culture positive 188 55 143 44 45 68 345 (286/59)
Convulsions 52 13 30 9 22 33 393 (327/66)
Consciousness disturbed 261 69 215 66 46 70 379 (316/63)
ICU-admission 77 20 69 21 8 12 392 (326/66)
Hearing loss 27 7 13 4 14 21 393 (327/66)
Meningitis with sepsis 170 43 147 45 23 35 393 (327/66)
Different numbers within groups are due to missing data in patient records.
Abbreviations: BM: bacterial meningitis, MM: meningococcal meningitis, PM: pneumococcal meningitis, CSF: cerebrospinal fluid, CRP: C-reactive protein, ICU: intensive
care unit.
doi:10.1371/journal.pone.0035837.t001
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cytotoxic effects and via activation of the immune response [35].
Experimental meningitis due to pneumolysin-deficient pneumo-
cocci causes less hearing loss than meningitis due to WT
pneumococci [36]. The innate immune response of TLR2/TLR4
double-knockout mice to intracisternal pneumococcal infection
was more severely impaired than that of mice lacking only TLR2
or TLR4 [37]. Inside the cochlea these receptors are also present.
Activation of these local TLRs then activates MyD88, which in
turn activates NFkB. MyD882/2 mice with experimental PM
show less cochlear inflammation than infected WT mice [38]. All
together, these findings show that an intact pathogen recognition
system via MyD88 is important for bacterial clearance from the
CNS but also responsible for inflammatory damage. TLR2, 4 and
9 are all involved in this pathway, explaining the significance of
our trait analysis.
No experimental studies on the mechanisms of hearing loss in
MM are published. However, since TLR2, 4 and 9 are also
activated by meningococcal PAMPs [10,21] we suggest that the
mechanism of TLR induced MyD88-dependant cochlear damage
might be similar to those in PM. Hyporesponsiveness to LPS
leading to higher bacterial loads in TLR4 SNP carriers might
enhance MyD88-dependant inflammation and subsequent dam-
age [14]. Upregulation of detrimental TLR4-mediated immune
responses might be an alternative explanation for hearing loss in
MM [39]. The TLR4+896 polymorphism is shown to change the
ligand-binding site of the receptor and results in a LPS hypo-
responsive phenotype [14]. In gene association studies, increased
Table 2. Genotypes of 11 studied polymorphisms in patients with meningococcal and pneumococcal meningitis.
SNP Genotype Total BM % MM % PM %
(n =393) (n =327) (n =66)
TLR2 -16934 T.A TT 107 27 89 27 18 27
(rs4696480) TA 184 47 150 46 34 52
AA 102 26 88 27 14 21
TLR2+2477 G.A GG 357 91 298 91 59 89
(rs5743708) GA 34 9 27 8 7 11
AA 2 1 2 1 0 0
TLR4+896 A.G AA 343 87 283 87 60 91
(rs4986790) AG 37 9 33 10 4 6
GG 13 3 11 3 2 3
TLR9 -1237 T.C TT 291 74 244 75 47 71
(rs5743836) TC 95 24 76 23 18 29
CC 7 2 7 2 0 0
TLR9+2848 G.A GG 90 23 79 24 11 17
(rs352140) GA 193 49 162 50 31 47
AA 110 28 86 26 24 36
NOD1+32556 T- . GG T-T- 225 57 183 56 42 64
(rs6958571) T-GG 148 38 126 39 22 33
GGGG 20 5 18 6 2 3
NOD2+2209 C.T CC 349 89 290 89 59 89
(rs2066844) CT 37 9 30 9 7 11
TT 7 2 7 2 0 0
NOD2+2722 G.C GG 384 98 318 97 66 100
(rs2066845) GC 7 2 7 2 0 0
CC 2 1 2 1 0 0
NOD2+3020 ins C 2/2 380 97 316 97 64 97
(rs5743293) 2/C 12 3 10 3 2 3
C/C 1 0 1 0 0 0
CASP1+8404 A.G AA 234 60 195 60 39 59
(rs2282659) AG 132 34 112 34 20 30
GG 27 7 20 6 7 11
TRAIL -692 T.C TT 317 81 266 81 51 77
(rs365238) TC 69 18 56 17 13 20
CC 7 2 5 2 2 3
Abbreviations: SNP: single nucleotide polymorphism, BM: bacterial meningitis, MM: meningococcal meningitis, PM: pneumococcal meningitis, TLR: Toll-like receptor,
NOD: nucleotide oligomerization domain protein, CASP: caspase, TRAIL: Tumor necrosis factor-related apoptosis inducing ligand.
doi:10.1371/journal.pone.0035837.t002
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susceptibility to Gram-negative infections has been demonstrated
[15,16], but results from meningococcal infections did not
consistently show this effect [7,40]. We suspect that other SNPs
might compensate for the TLR4 mediated hyporesponsiveness to
LPS, as we show in the carrier trait analysis. Combined carriership
of TLR2+2477 GG (WT) and TLR4+896 AG (mutants) increased
the risk to develop post-meningitis hearing loss, indicating that
TLR2 SNPs compensate for TLR4 mutant hyporesponsiveness.
Carriage of one or more mutants in combined carriership of
TLR4+896 and TLR9 -1237 increases the risk for hearing loss in
BM patients. The link between TLR4 and TLR9 was also shown
in a murine in vitro study on macrophage cytokine production
upon TLR9 mediated CpG DNA stimulation. Pretreatment of
these macrophages with TLR4 mediated LPS heightened the
TNF-a and IL-6 production [41]. Recent evidence indicates that
the TLR9 -1237 C allele results in an increased TLR9 initiated
immune response via an extra putative binding site for NFkB [41],
which may lead to increased immune-mediated cochlear damage.
Another study on TLR9 -1237 SNPs showed higher serum
Interferon gamma levels in children with cerebral malaria,
indicating that enhanced TLR9 mediated immune responses are
also relevant inside the CNS [42].
This study consists of a unique large cohort of survivors of BM
in childhood including genetic as well as clinical data. Since we
used two independent cohorts, internal validation has been
applied. However, interpretation of the results of this study has
some limitations. Sample sizes were small for the pneumococcus-
and for the hearing loss- groups. Different results were found for
S. pneumoniae and N. meningitidis. This may either be due to an
increased incidence of hearing loss in the PM group (21%)
compared to 4% in the MM group, or to differences in
pathogenesis and recognition of these two different pathogens by
TLR9. TLR9 is shown to recognize both meningococci and
pneumococci, but the ability to activate TLR9 was severely
attenuated when bacteria had been heat-inactivated prior to
stimulation in vitro [43]. Since S. pneumoniae is associated with
higher bacterial loads in the CSF compared to N. meningitidis, the
presence of a higher bacterial load in PM in the cochlea may
also explain the stronger association in PM with hearing loss.
In order to assess the influence of clinical as well as genetic
factors on the course of disease, larger numbers of patients and
SNPs are needed preferably with prospective data and an
association study should be repeated in a third, large preferable
ethnically different cohort in the future to confirm the associations
we found. Other SNPs involved in the bacterial infection might be
relevant in BM e.g. macrophage migration inhibitory factor (MIF)
Toll-interleukin 1 receptor domain containing adaptor protein
(TIRAP) and complement mediated inflammation.
Our study provides evidence that SNPs in pathogen recognition
receptor genes affect the severity of disease in a specific way. It
should be mentioned that this type of study is hypothesis
generating, but does not prove causation. The exact mechanisms
how these SNPs affect the course of disease and hearing loss in
particular are an interesting focus of further research in
experimental models.
Determination of SNPs in an early stage of BM may be useful to
identify children at risk to develop sequelae and to add host genetic
markers to current clinical prediction rules on complications after
BM such as hearing loss and academic and behavioral limitations
[44,45].
Indentifying high risk patients may also provide opportunities
for specific individual therapeutic modifications to prevent the
damage that occurs during the necessary immune response aimed
at bacterial clearance from the CNS. Unraveling the molecular
basis of the inflammatory responses inside the CNS might facilitate
the development of specific and targeted anti-inflammatory
therapy in high-risk patients.
Table 3. Genotype distributions compared between clinical severity groups.
SNP Severity variable n (%) X
2/Fisher exact
p, OR (95% CI)
BM MM PM BM MM PM
n % n % n % n % n % n %
TLR4+896 Hearing loss No hearing loss AA vs AG/GG
AA 18 67 7 54 11 79 325 89 276 88 49 94 BM 0.001**, 4.0 (1.7–9,4)
AG 8 30 5 39 3 21 29 8 28 9 1 2 MM 0.0004**, 6.2 (2.0–19.5)
GG 1 4 1 8 0 0 12 3 10 3 2 4 PM NS
TLR9-1237 Hearing loss No hearing loss TT vs TC/CC
TT 15 56 9 69 6 43 276 75 235 75 41 79 BM 0.023*, 2.5 (1.1–5.4)
TC 12 44 4 31 8 57 83 23 72 23 11 21 MM NS
CC 0 0 0 0 0 0 7 2 7 2 0 0 PM 0.017, 5.0 (1.4–17.4)
CASP1+8404 Fever No fever AA/AG vs GG
AA 194 61 158 62 36 59 21 47 20 47 1 50 BM 0.01*, 0.3 (0.1–0.8)
AG 106 33 86 34 20 33 17 38 17 40 0 0 MM 0.018, 0.3 (0.1–0.9)
GG 17 5 12 5 5 8 7 16 6 14 1 50 PM NS
*p,0.05.
**p,0.003 (p significance corrected for multiple testing according to Holm-Bonferroni).
Different numbers between groups are due to missing data.
Abbreviations: SNP: single nucleotide polymorphism, OR: Odds ratio, CI: confidence interval, TLR: Toll-like receptor, BM: bacterial meningitis, MM: meningococcal
meningitis, PM: pneumococcal meningitis, CASP1: caspase-1, NS: not significant.
doi:10.1371/journal.pone.0035837.t003
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Materials and Methods
Patients
Figure 1 shows a flow chart of patient inclusion in this study. The
cohort of school age children in part with post-meningitis hearing
loss is composed of two independent cohorts. Both cohorts were
described in detail in other studies [44,45]. Both cohorts appeared
to be rather similar [46] and no significant differences in genotype
distributions were observed between both cohorts. Only Dutch
Caucasian survivors of PM and MM were selected for this study.
Six hundred sixty nine (669) patients were eligible for our study
and were asked to participate in the study and to return a sterile
swab after collecting their buccal DNA. Of these patients a total of
471 (70%) returned a buccal swab and an informed consent form.
Only samples with high quality DNA in which all eleven SNPs
could be genotyped after three distinct Taqman and/or Lightcyler
analyses were included in this study (n =393 including 327 MM
patients and 66 PM patients). The median age of all patients at the
time of infection was 2.2 years-old (range 0.1–9.5), 56% were male
and 44% were female. All patients were selected from data on
bacterial CSF isolates of the Netherlands Reference Laboratory
for Bacterial Meningitis (NRLBM). The NRLBM receives
approximately 90% of the isolates of Dutch meningitis patients.
The diagnosis meningitis was based on the demonstration of
pathogens or antigens against PM or MM in the CSF by culture.
Children with ‘complex onset’ of meningitis (defined as meningitis
secondary to immune deficiency states, cranial trauma, CNS
surgery, and CSF shunt infections, meningitis in the neonatal
period) or relapsing meningitis were not included. The Medical
Figure 1. Flow chart of patient inclusion in this study.
doi:10.1371/journal.pone.0035837.g001
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Ethical Committee of the VU University Medical Center
approved this study.
Clinical Variables
Data on medical history, physical examination, clinical course
during hospitalization, and laboratory results were gathered
retrospectively from the medical records of all patients. Detailed
information on CSF culture results was collected from the
NRLBM. We used clinical factors with regard to severity and
outcome of BM in children that could potentially be linked to
genetic variation as currently accepted in literature. These
variables were in concordance with a recent systematic review
summarizing the evidence regarding prognostic factors predicting
death or sequelae after BM in children [47]. Only variables with
a reasonable incidence (.5% cases) were included. Continuous
clinical severity variables include: duration of clinical illness before
admission and rectal temperature at admission. Rectal tempera-
ture was dichotomized to the presence of fever, i.e. rectal
temperature $38uC. Continuous laboratory values at admission
include: CSF leukocyte number, CSF/blood glucose ratio, CSF
protein concentration, blood leukocyte number, CRP concentra-
tion. The dichotomous severity variables include: causing patho-
gen in CSF culture, meningitis causing pathogen in blood culture,
convulsions present, disturbed consciousness at admission, ICU-
admission, post-meningitis hearing loss, and meningitis with or
without sepsis.
Convulsions were defined as convulsions reported before or at
admission or during hospitalization. Hearing loss was defined as
an unilateral or bilateral perceptive hearing loss .25 dB that was
not present before meningitis occurred and was based on
information from medical records and parental information
provided from questionnaires about the children’s health [44].
Conductive hearing loss was not included.
Missing Data
Patients in which not all 11 SNPs could be genotyped after
3 PCR assays were excluded in order to increase the continuity of
our data (figure 1). Missing clinical data (Table 1) range from 0% in
most cases to 40% in CRP.
DNA Isolation
DNA was isolated from the buccal swabs using the following
procedure: after addition of 250 ml 10 mM Tris-HCl (pH 7.4) the
sample was heated at 96 degrees Celsius for 10 minutes. After
mixing for 10 seconds the swabs were removed and the sample was
centrifuged (14.000 rpm).
Genotyping
All samples were genotyped for the TLR2 -16934 T.A (NCBI
SNP CLUSTER ID: rs4696480), TLR2+2477 G.A (rs5743708),
TLR4+896 A.G (rs4986790), NOD1+32556 (T-.GG)
(rs6958571), NOD2+2209 C.T (rs2066844), NOD2+2722 G.C
(rs2066845), NOD2+3020 ins C (rs5743293), CASP1+8404 A.G
(rs2282659), and TRAIL -692 T.C (rs365238) SNPs by real-time
PCR using the TaqMan AbiPrismH 7000 Sequence Detection
System (Applied Biosystems, UK) with the standard TaqMan
protocol and the the LightCyclerH 480 System (Roche Applied
Science, US). Results were analyzed by two independent
researchers. TLR9 -1237 T.C (rs5743836) and
TLR9+2848 G.A (rs352140) were genotyped in a previous study
[5] and were used in this multigene study.
Statistics
Prior to this study power analyses were performed using
G*Power 3.1. Since no prior SNP frequencies in BM patients with
hearing loss was available we had to estimate the distribution in
cases on similar studies and experience.
Within selected severity groups, we compared the distribution of
SNP alleles. For statistical analysis, SPSS for Windows 17.0 (IBM
Corporation, Somers, New York) and Graphpad Instat PrismH 5
were used. Genotype frequencies of all 11 SNPs were compared
between the aforementioned severity groups. Genotypic models of
inheritance were used to assess the relation between genetic and
clinical variables. Significant associations were further explored for
recessive or dominant models. Histograms were used to assess
normality. T-tests, Mann-Whitney U tests, and x2 test or Fisher’s
exact tests were used where appropriate. Outliers were excluded
(,4%) by the Grubbs’ test (p,0.01) before continuous testing.
Next, continuous variables were dichotomized based on clinical
relevant cut-off points as described in literature [44,45] or as used
in clinical practice. After Holm-Bonferroni correction for multiple
testing, p-values ,0.003 were considered to be statistically
significant.
Multigene Analysis
Combinations of SNPs within the same gene or in the same
biological pathway were studied in variables that showed
a significant or trend association in one of the SNPs. Studied
combinations of SNPs are: TLR2 -16934, TLR2+2477, and
TLR4+896 (stimulating MyD88 via TIRAP and triggering the
intracellular signaling cascade), TLR4+896, TLR9-1237 and
TLR9+2848 [48] (activating the MyD88 pathway) and the three
NOD2 SNPs (+2209, +2722 and +3020).
Clinical and genetic variables were modeled using backward
stepwise logistic regression.
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